Oncology Baltimore
Dr. Mark Yarchoan is an Associate Professor of Oncology at the Johns Hopkins University School of Medicine and a physician-scientist specializing in liver cancer, cancer immunotherapy, and therapeutic cancer vaccines. His clinical and research interests focus on hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and fibrolamellar carcinoma (FLC). Dr. Yarchoan leads an NIH-funded translational research laboratory focused on understanding mechanisms of response, resistance, and toxicity associated with immunotherapy in solid tumors, as well as developing novel immunotherapies. His early research contributed to establishing the association between tumor mutational burden (TMB), neoantigens, and clinical responses to immunotherapy. A major focus of his research has been the development of therapeutic cancer vaccines targeting tumor-specific neoantigens, including personalized vaccines and "off-the-shelf" vaccines directed against shared oncogenic alterations. Dr. Yarchoan has led several pioneering clinical trials in liver cancer immunotherapy including the first trial of neoadjuvant anti-PD-1 immunotherapy for HCC and the first clinical trial of a personalized neoantigen vaccine for HCC. Together with his colleague Dr. Marina Baretti, he also developed an off-the-shelf therapeutic cancer vaccine targeting the DNAJB1-PRKACA oncogenic fusion in fibrolamellar carcinoma, and an oncogene-targeted vaccine program in CCA. Dr. Yarchoan contributes to international consensus and clinical practice guidance for liver cancer, including serving as co-chair of the BEACON-HCC classification system. He is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his internal medicine residency at the Hospital of the University of Pennsylvania and his medical oncology fellowship at Johns Hopkins, where he joined the faculty in 2018. His contributions to cancer research have been recognized with multiple honors, including the ASCO Young Investigator Award, Conquer Cancer Foundation Career Development Award, Mark R. Clements Award from the Cholangiocarcinoma Foundation, and Blue Faery Award for Excellence in Liver Cancer Research. In 2026, he was elected to the American Society for Clinical Investigation (ASCI).
By Appointment Only